Evaluate the Safety and Tolerability of JCXH-212 Injection in the Treatment of Advanced Malignant Solid Tumors

A Single-center, Open-label Study to Evaluate the Safety and Tolerability of JCXH-212 Injection in the Treatment of Advanced Malignant Solid Tumors

To evaluate the safety and tolerability of JCXH-212 injection in patients with advanced malignant solid tumors; to determine the maximum tolerated dose (MTD), and to evaluate the dose-limiting toxicity (DLT) of JCXH-212 injection.

Study Overview

• Status: Recruiting
• Conditions: Advanced Malignant Solid Tumors
• Intervention / Treatment: Biological: JCXH-212 Injection

Detailed Description

This study uses 3+3 clinical design.About 12-24 patients with advanced solid tumor malignancies are expected to be enrolled in this study. A total of four dose groups were set for dose escalation. Doses were administered every 21 days, with a DLT observation period of 21 days after the first dose. After completion of DLT assessment, the investigator decided whether to continue the treatment after the end of DLT assessment based on the subject 's tolerance and the safety profile of the dose group. Subjects may continue to receive dosing every 21 days if the investigator determines that the subject is benefiting from continued treatment. No more than 8 total doses were administered.

• Study Type: Interventional
• Enrollment (Anticipated): 24
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Zhuo Minglei, Physician; Phone Number: 010-88196456; Email: trialminglei@126.com

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100042
      • Recruiting
      • Peking University Cancer Hospital & Institute
      • Contact: Zhuo Minglei, professor; Phone Number: 010-88196456; Email: trialminglei@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• The enrolled subjects shall meet all the following conditions at the same time:

  1. male or female patients, aged 18 ~ 75 years old;
  2. patients with advanced malignant solid tumors who have failed standard treatment (progression or intolerance after treatment) confirmed by pathology and/or cytology;
  3. tumor biopsy tissue samples can be provided for tumor neoantigen detection;
  4. ECOG (Eastern Cooperative Oncology Group) score of 0 ~ 1 in general condition;
  5. expected survival time of more than 3 months;
  6. patients have at least one measurable tumor lesion according to Response Evaluation Criteria in Solid Tumors (RECISTv1.1), the longest diameter at baseline is ≥ 10 mm (if lymph nodes, the short diameter is ≥ 15 mm);

  7. patients shall have sufficient bone marrow reserve function, and have no liver and kidney coagulation dysfunction, and laboratory test values shall meet the following conditions:

     1. absolute neutrophil count > 1.5 × 10/L,And white blood cell count > 3 × 10/L;
     2. platelet count > 80 × 10/L;
     3. hemoglobin > 90 g/L;
     4. serum creatinine < 1.5 × upper limit of normal (ULN) and creatinine clearance calculated by Cockroft-Gault formula > 30 mL/min;
     5. if there is no confirmed liver metastasis, AST, ALT < 2.5 × ULN; if there is confirmed liver metastasis, AST, ALT < 5 × ULN;
     6. if there is no liver metastasis, total bilirubin < 1.5 × ULN; if there is liver metastasis or Gilbert 's syndrome (hyperindirect bilirubinemia), total bilirubin < 3 × ULN;
     7. international normalized ratio (INR) < 1.5, and activated partial prothrombin time (APTT) < 1.5 × ULN;
  8. tumor tissue gene detection suggests that one or more vaccines contain positive tumor neoantigen expression;
  9. patients do not have brain metastasis (except asymptomatic or stable brain metastasis after treatment for more than four weeks);
  10. Any adverse reactions caused by previous treatment must have recovered to grade 0-1 (except alopecia and vitiligo) within 4 weeks before the first dose of study drug;

  11. Patients voluntarily signed informed consent and expected compliance.

      Exclusion Criteria:

• Those meeting any of the following conditions may not be included.

  1. Known or suspected hypersensitivity to the ingredients of the study drug or its analogues;
  2. Patients with any other disease or medical condition that is unstable or may affect their safety or study compliance, any serious or uncontrolled systemic disease, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, active gastrointestinal ulcers, abnormal immune function, etc.;

  3. Cardiovascular and cerebrovascular diseases/symptoms/indications that meet any of the following conditions:

     1. mean resting QTc > 470 ms (corrected QT interval [corrected by Fridericia formula]), mean QTc of 3 ECGs, QT interval measurement should start from QRS complex to the end of T wave);
     2. any clinically significant resting ECG abnormalities in rhythm, conduction or morphology, such as complete left bundle branch block, grade 2 and 3 heart block, PR interval > 250 ms, etc.;
     3. any factor that increases the risk of QTc prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, etc. or unexplained sudden death in a first-degree relative under 40 years of age, or any concomitant medication known to prolong the QT interval;
     4. left ventricular ejection fraction (LVEF) < 50%;
     5. previous history of decreased myocardial contractility, i.e.Patients who presented with relevant symptoms within 6 months before study drug administration: such as chronic congestive heart failure, pulmonary edema or decreased cardiac ejection fraction;
     6. patients who had a history of acute or chronic cardiovascular and cerebrovascular diseases and presented with relevant symptoms within 6 months before study drug administration: myocardial infarction, severe or unstable angina pectoris, cerebral infarction, cerebral hemorrhage, or transient ischemic attack;
  4. . Patients who had an active second primary malignant tumor within 2 years before the first dose of study drug, except for specific cancers to be investigated and locally recurrent cancers that had undergone radical treatment (such as resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast carcinoma in situ);
  5. . Patients with uncontrollable malignant third space effusion;
  6. . For women of childbearing age (postmenopausal women must have been postmenopausal for at least 12 months to be considered of non-childbearing potential), positive serum pregnancy test results within 7 days before the first dose of study drug;

  7. Within 4 weeks before the first dose of study drug:

     1. received chemotherapy, radiotherapy, biological/targeted drug therapy, immune drug therapy and other anti-tumor therapy;
     2. received major surgery;
     3. participated in other clinical trials,Use or ongoing treatment with other investigational agents (other than non-interventional drug clinical trials);
     4. history of vaccination;
  8. other severe, acute, or other severe forms that may increase the risk of study and study medication or may interfere with study results Or chronic clinical or psychiatric disorders or laboratory abnormalities;

  9. patients with active autoimmune diseases or history of autoimmune diseases but may relapse, but patients with the following diseases are not excluded and can be further screened:

     1. type I diabetes;
     2. hypothyroidism (if controlled with hormone replacement therapy alone);
     3. controlled celiac disease;
     4. skin diseases that do not require systemic treatment (e.g., vitiligo, psoriasis, alopecia) ;
     5. any other disease that does not recur in the absence of external triggers;

  10. active human immunodeficiency virus (HIV), syphilis, hepatitis C virus (HCV) or hepatitis B virus (HBV) infection, asymptomatic chronic hepatitis B or C carriers can be excluded; active HBV, HCV and HIV infection is defined as:

      1. HBsAg positive and HBV DNA ≥ 1000 cps/ml (or 200 IU/ml);
      2. anti-HCV antibody and HCV RNA positive;
      3. HIV antibody positive;
  11. Active infection and need anti-infection treatment;
  12. Patients with a history of organ transplantation;
  13. Any form of primary immunodeficiency (such as severe combined immunodeficiency disease);
  14. Within 7 days before the first dose of the study drug,Receiving any systemic steroid therapy or other form of immunosuppressive therapy;
  15. The investigator believes that the patient is not suitable for this trial for any reason.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: cohort-experimental; Patients will receive treatment observation every 21 days for up to 8 cycles. Actual follow-up will be decided according to the patient 's condition and benefit, and each test requirement and data collection will be completed at specified time during the follow-up cycle.

Biological: JCXH-212 Injection; Based on the development principle of NCV, a community-type tumor neoantigen mRNA vaccine, JCXH-212 injection, has been developed that can be applied to patients with advanced malignant solid tumors. NCVs activate tumor-specific CD4+ T cells and CD8+ T cells through active immunity, and these T cells can inhibit and kill tumor cells in cancer patients, thus prolonging the survival of cancer patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
dose-limiting toxicity (DLT)	Tolerability and safety analysis: determine the maximum tolerated dose (MTD) and determine the escalation of the relevant dose. Incidence of DLTs was summarized overall and by dose level based on the DLT Analysis Set (DLTS).	Up to 21 days after first dose every subject
analysis of primary efficacy indicators	Efficacy analysis: In the study, correlation analysis will be performed between the main efficacy indicators and dose regimen in each dose group.	At the end of the time 3-6 months after last subject last dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
exploratory analysis of changes in peripheral blood neoantigen-specific T cell responses before and after administration	Exploratory analysis: focus on describing changes in peripheral blood neoantigen-specific T cell responses before and after administration and the possible association or predictive role of such changes with treatment outcome	The day of administration of the last subject

Collaborators and Investigators

• Sponsor: Peking University Cancer Hospital & Institute
• Investigators: Principal Investigator: Zhuo Minglei, Physician, Peking University Cancer Hospital & Institute; Study Chair: zhuo Minglei, Physician, Peking University Cancer Hospital & Institute

Study record dates

Study Major Dates

• Study Start (Actual): January 4, 2023
• Primary Completion (Anticipated): January 28, 2024
• Study Completion (Anticipated): April 25, 2024

Study Registration Dates

• First Submitted: September 30, 2022
• First Submitted That Met QC Criteria: October 11, 2022
• First Posted (Actual): October 13, 2022

Study Record Updates

• Last Update Posted (Actual): April 10, 2023
• Last Update Submitted That Met QC Criteria: April 6, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: 2021-JCXH-212-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No